CLOs on the Move

Pathalys

www.pathalys.com

 
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.pathalys.com
  • 4242 Six Forks Road Suite 820
    Raleigh, NC USA 27609
  • Phone: n/a

Executives

Name Title Contact Details

Similar Companies

Veranova

Veranova is a global leader in process development and manufacturing of active pharmaceutical ingredients (APIs), focused on specialty niches with expertise in highly regulated and complex chemistries. Veranova is headquartered in Wayne, PA and has operations in North America and Europe.

Orcabio

Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients` diseased blood and immune system with a healthy one.

Family Discount Pharmacy

Family Discount Pharmacy is a Carmichael, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Touchstone Health Services

Touchstone partners with individuals, families, schools and other service providers to deliver the optimal continuum of health, education, social services

Syros

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company’s gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RARα agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.